2015
DOI: 10.1016/j.nano.2015.02.008
|View full text |Cite
|
Sign up to set email alerts
|

Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses

Abstract: Recombinant virus-like nanoparticles (VLPs) are a promising nanoparticle platform to develop safe vaccines for many viruses. Herein, we describe a novel and rapid protein transfer process to enhance the potency of enveloped VLPs by decorating influenza VLPs with exogenously added glycosylphosphatidylinositol-anchored immunostimulatory molecules (GPI-ISMs). With protein transfer, the level of GPI-ISM incorporation onto VLPs is controllable by varying incubation time and concentration of GPI-ISMs added. ISM inco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
45
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 22 publications
(46 citation statements)
references
References 40 publications
1
45
0
Order By: Relevance
“…FDA-approved treatments include the HER2-specific antibodies trastuzumab and pertuzumab, which are used for passive immunotherapy and require repetitive administration 162, 163 . Passive immunization requires prolonged therapeutic delivery, cannot be developed as a prophylactic, and does not induce cellular immune responses 77, 78 . To overcome these challenges, HER-2 + breast cancer research is now focused on active immunotherapy that elicits long-lasting cellular and humoral responses.…”
Section: Vnp and Vlp Vaccines And Immunotherapiesmentioning
confidence: 99%
“…FDA-approved treatments include the HER2-specific antibodies trastuzumab and pertuzumab, which are used for passive immunotherapy and require repetitive administration 162, 163 . Passive immunization requires prolonged therapeutic delivery, cannot be developed as a prophylactic, and does not induce cellular immune responses 77, 78 . To overcome these challenges, HER-2 + breast cancer research is now focused on active immunotherapy that elicits long-lasting cellular and humoral responses.…”
Section: Vnp and Vlp Vaccines And Immunotherapiesmentioning
confidence: 99%
“…Using a protein transfer technology, glycosylphosphatidylinositolanchored immunostimulatory molecules (GPI-ISMs) are incorporated onto influenza VLPs [83]. Mice immunized with VLPs modified by protein transfer with GPI-GM-CSF induced higher levels of IgG antibody responses and protection against a heterologous influenza virus challenge than unmodified VLPs in mice [83]. Intranasal immunization with chimeric VLPs containing influenza HA antigen and GPI-CCL28 was shown to induce long-lasting mucosal immunity against H3N2 virus infection [84].…”
Section: Chimeric Influenza or Adjuvanted Vlps Vaccinesmentioning
confidence: 99%
“…A recent study described a novel protein transfer technology to enhance the potency of enveloped VLPs by decorating influenza VLPs with exogenously added glycosylphosphatidylinositol-anchored (GPI) granulocyte macrophage colony-stimulating factor (GM-CSF) [44]. Incorporation of immunostimulatory GM-CSF into influenza VLPs was dependent on the presence of GPI-anchor, and found to be stable and functional.…”
Section: Novel Vlps To Improve the Cross Protective Efficacymentioning
confidence: 99%